Premium
Phospholipase D as a key modulator of cancer progression
Author(s) -
Yao Yuanfa,
Wang Xinyi,
Li Hanbing,
Fan Jiannan,
Qian Xiaohan,
Li Hong,
Xu Yingke
Publication year - 2020
Publication title -
biological reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.993
H-Index - 165
eISSN - 1469-185X
pISSN - 1464-7931
DOI - 10.1111/brv.12592
Subject(s) - phospholipase d , pld2 , metastasis , cancer , cancer research , angiogenesis , cancer cell , effector , biology , microbiology and biotechnology , phosphatidic acid , intracellular , chemistry , signal transduction , biochemistry , genetics , membrane , phospholipid
The phospholipase D (PLD) family has a ubiquitous expression in cells. PLD isoforms (PLDs) and their hydrolysate phosphatidic acid (PA) have been demonstrated to engage in multiple stages of cancer progression. Aberrant expression of PLDs, especially PLD1 and PLD2, has been detected in various cancers. Inhibition or elimination of PLDs activity has been shown to reduce tumour growth and metastasis. PLDs and PA also serve as downstream effectors of various cell‐surface receptors, to trigger and regulate propagation of intracellular signals in the process of tumourigenesis and metastasis. Here, we discuss recent advances in understanding the functions of PLDs and PA in discrete stages of cancer progression, including cancer cell growth, invasion and migration, and angiogenesis, with special emphasis on the tumour‐associated signalling pathways mediated by PLDs and PA and the functional importance of PLDs and PA in cancer therapy.